<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The pharmacological properties of YM-57029 [4-[4-(4-carbamimidoylphenyl)-3-oxopiperazin-1-yl]piperidino]<z:chebi fb="22" ids="15366">acetic acid</z:chebi> monohydrochloride trihydrate), a novel <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> were examined in this study </plain></SENT>
<SENT sid="1" pm="."><plain>YM-57029 inhibited fibrinogen binding to purified <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa, 1000-fold more potently than the <z:chebi fb="0" ids="48030">tetrapeptide</z:chebi> arginine-glycine-aspartic acid-serine (RGDS) </plain></SENT>
<SENT sid="2" pm="."><plain>YM-57029 concentration-dependently inhibited <z:chebi fb="13" ids="16761">ADP</z:chebi>-, collagen- and high shear stress-induced platelet aggregation, strongly inhibited ATP release from platelets activated by <z:chebi fb="13" ids="16761">ADP</z:chebi>, and enhanced deaggregation of <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregates </plain></SENT>
<SENT sid="3" pm="."><plain>In a pro-aggregatory activity study, RGDS or SC-54701A ((S)-3-[3-[(4-amidinophenyl)<z:chebi fb="0" ids="23004,33100">carbamoyl</z:chebi>]propionamido]-4-pentynoic acid monohydrochloride) caused prominent small aggregate formation </plain></SENT>
<SENT sid="4" pm="."><plain>At a higher concentration, RGDS induced medium and large size aggregates, and SC-54701A induced medium aggregates </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, YM-57029 produced only a few small and no larger size aggregates </plain></SENT>
<SENT sid="6" pm="."><plain>Ex vivo <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation and platelet retention to collagen-coated plastic beads were dose-dependently inhibited by YM-57029 after intravenous bolus injection in guinea pigs </plain></SENT>
<SENT sid="7" pm="."><plain>YM-57029 produced dose-dependent antithrombotic effects in carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and arterio-venous shunt <z:mp ids='MP_0005048'>thrombosis</z:mp> models in guinea pigs at 10 and 30 microg/kg, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>At these doses, YM-57029 prolonged template <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that YM-57029 is a potent <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> which has less pro-aggregatory effect </plain></SENT>
<SENT sid="10" pm="."><plain>It may be a promising antiplatelet agent for <z:hpo ids='HP_0001907'>thromboembolic diseases</z:hpo>, and a good prototype for developing an orally active compound </plain></SENT>
</text></document>